A detailed history of Stonebridge Capital Management Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Stonebridge Capital Management Inc holds 735 shares of REGN stock, worth $781,745. This represents 0.33% of its overall portfolio holdings.

Number of Shares
735
Previous 735 -0.0%
Holding current value
$781,745
Previous $707,000 9.34%
% of portfolio
0.33%
Previous 0.32%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Dec 13, 2023

SELL
$692.45 - $844.37 $6,924 - $8,443
-10 Reduced 1.34%
735 $605,000
Q4 2022

Jan 06, 2023

SELL
$705.89 - $766.39 $123,530 - $134,118
-175 Reduced 19.02%
745 $538,000
Q2 2020

Jul 07, 2020

SELL
$493.32 - $643.92 $24,666 - $32,195
-50 Reduced 5.15%
920 $560,000
Q1 2020

May 20, 2020

SELL
$336.18 - $494.43 $16,809 - $24,721
-50 Reduced 4.9%
970 $474,000
Q4 2019

Jan 02, 2020

SELL
$274.13 - $376.51 $20,559 - $28,238
-75 Reduced 6.85%
1,020 $383,000
Q3 2019

Oct 02, 2019

SELL
$273.46 - $318.39 $88,601 - $103,158
-324 Reduced 22.83%
1,095 $304,000
Q2 2019

Jul 12, 2019

SELL
$299.6 - $414.82 $221,704 - $306,966
-740 Reduced 34.28%
1,419 $445,000
Q1 2019

May 02, 2019

SELL
$372.08 - $439.57 $22,324 - $26,374
-60 Reduced 2.7%
2,159 $887,000
Q4 2018

Jan 25, 2019

SELL
$335.82 - $403.04 $8,395 - $10,076
-25 Reduced 1.11%
2,219 $829,000
Q3 2018

Oct 17, 2018

SELL
$351.14 - $408.51 $89,540 - $104,170
-255 Reduced 10.2%
2,244 $907,000
Q2 2018

Jul 06, 2018

BUY
$284.6 - $344.99 $47,243 - $57,268
166 Added 7.12%
2,499 $902,000
Q1 2018

Apr 16, 2018

BUY
$315.82 - $393.78 $191,071 - $238,236
605 Added 35.01%
2,333 $750,000
Q4 2017

Jan 29, 2018

BUY
$358.63 - $469.95 $619,712 - $812,073
1,728
1,728 $634,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $114B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Stonebridge Capital Management Inc Portfolio

Follow Stonebridge Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonebridge Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Stonebridge Capital Management Inc with notifications on news.